What Impact Does Lowering Hemoglobin A1c Have on Life Expectancy and Healthspan?
Updated: 7 days ago
The A1c test, also called the hemoglobin A1c or HbA1c test, measures your average blood sugar over the previous two to three months. A finger-prick blood sugar test captures one moment; this one captures a season, which is what makes it the most useful single number on a routine lab panel for judging long-term metabolic health. The diagnostic bands and what each one means are set out below, along with what the evidence says about lowering the number and how to go about it.
Key takeaways
A1c reflects roughly three months of blood sugar, not this morning's reading, so it is harder to game and more useful for tracking real change.
In the UK Prospective Diabetes Study, each 1% drop in A1c was linked to 21% fewer diabetes-related deaths, 14% fewer heart attacks and 37% fewer microvascular complications, with the lowest risk in people with type 2 diabetes under 6.0%.
Type 2 diabetes diagnosed a decade earlier is associated with roughly three to four years of lower life expectancy, so the age at which your A1c starts climbing matters as much as the number itself.
Diet, weight loss and continuous glucose monitoring all move A1c. In the DiRECT trial, 86% of the participants who lost 15 kg or more went into remission, though only 24% of the intervention group reached that much weight loss.
Very aggressive targets are not right for everyone. Anyone taking insulin or a sulfonylurea should set their A1c goal with a physician, not on their own.
Hemoglobin A1c (HbA1c) is more than just a number; not only is HbA1c a key indicator of how well diabetes is being managed, but it is extremely important in the context of anti-aging medicine, preventative medicine, and how it influences overall health.
The HbA1c offers a window into average blood glucose levels over the previous two to three months, making it crucial for understanding long-term health. Lowering HbA1c levels can lead to significant improvements in life expectancy and healthspan, the period during which individuals feel their best. Interestingly, it gives you a significant clue as to how much damage is being done to the inner linings of your blood vessels, even prior to the development of heart or vascular disease.
What is a normal A1c level?
Three numbers do most of the work here, and they come from the Centers for Disease Control and Prevention:
Below 5.7% is normal.
5.7% to 6.4% is prediabetes.
6.5% or higher meets the threshold for a diabetes diagnosis.
For people already living with diabetes, the American Diabetes Association puts the usual treatment target at 7% or less. That is a treatment target, not a health optimum, and the two are often confused. A result of 6.7% is not a crisis, but it is above the diabetic threshold and worth acting on.
The prediabetes band is where most of the opportunity sits, because it is the point at which progression to type 2 diabetes is most preventable. In the Diabetes Prevention Program, a lifestyle program targeting 7% weight loss and 150 minutes of activity a week cut the incidence of diabetes by 58% over an average of 2.8 years in people with raised fasting and post-load glucose (Knowler et al., New England Journal of Medicine, 2002). We cover that window in more detail in our article on pre-diabetes and insulin resistance.
The Maillard Reaction
The role of HbA1c is closely tied to the Maillard reaction, a chemical process that occurs when sugars and amino acids combine. While this reaction often enhances the flavor and color in our cooked foods, it also generates harmful compounds known as advanced glycation end products (AGEs). AGEs have been shown to negatively impact health, leading to chronic diseases that can accelerate aging. AGEs accumulate faster when blood sugar runs high, and their build-up is associated with inflammation, arterial stiffening and the vascular complications seen in type 2 diabetes (Prasad et al., Advanced Glycation End Products and Risks for Chronic Diseases).
In short, this is the simple, chemical explanation of why glucose (sugar) in your blood stream can be damaging to your health.
Benefits of Lowering HbA1c
High HbA1c levels indicate poor blood sugar management, leading to complications spanning multiple organ systems. Research has demonstrated a clear relationship between lowering HbA1c and increased longevity. The landmark UK Prospective Diabetes Study (UKPDS 35, Stratton et al., BMJ 2000) analysed 3,642 patients in the relative-risk analysis and found that each 1% reduction in mean HbA1c was associated with 21% fewer deaths related to diabetes, 14% fewer myocardial infarctions and 37% fewer microvascular complications. Risk was lowest in those whose HbA1c sat in the normal range, below 6.0%.
When HbA1c values dip, the associated risks for chronic health issues, such as neuropathy and retinopathy, decrease significantly. The microvascular endpoint behind that 37% figure was predominantly retinopathy needing laser photocoagulation, which is why small-vessel disease responds so strongly to glycemic control. This stewardship over blood sugar levels not only extends lifespan but also lengthens healthspan, maximizing the years individuals remain active and engaged.
The life expectancy question has a direct answer. Pooling 23 million person-years across 19 high-income countries, the Emerging Risk Factors Collaboration found that every decade earlier a person is diagnosed with type 2 diabetes is associated with roughly three to four years of lower life expectancy (Lancet Diabetes & Endocrinology, 2023). A diagnosis at 30 rather than 50 is not a minor difference in timing. It is the difference between two quite different life spans, which is why catching a rising A1c in the prediabetic range matters more than almost anything else on a routine lab panel.
NOTE WELL: For optimal metabolic control and longevity, reducing blood glucose to an ideal range (between 70 and 85 mg/dL) and achieving hemoglobin A1c less than 5% are important goals. Maintaining optimal HbA1c levels is vital for extending healthspan, as high HbA1c levels indicate poor long-term blood glucose control and are linked to numerous health risks. This is not an easy goal to achieve, but it is most certainly achievable.
Two cautions belong alongside that goal. The first applies whether or not you take medication. An A1c under 5% is an optimization target for a metabolically healthy person, not a blanket instruction, and the evidence in people without diabetes does not point to lower being better without limit: in 11,092 adults without diabetes in the ARIC study, HbA1c and death from any cause followed a J-shaped curve measured against a reference band of 5.0% to under 5.5%, meaning risk was higher both above and below that band (Selvin et al., New England Journal of Medicine, 2010). The second applies if you are on treatment. The ACCORD trial found that targeting an A1c below 6% with intensive drug therapy in high-risk patients with established type 2 diabetes increased mortality rather than reducing it; the intensive arm reached a median of 6.4% (New England Journal of Medicine, 2008). If you take insulin or a sulfonylurea, the risk of hypoglycemia makes this a conversation to have with your physician before changing anything, and a fasting glucose target as low as 70 mg/dL sits at the level at which hypoglycemia is conventionally defined.
How to Lower Your A1c: Lifestyle Changes That Make a Difference
Five changes account for most of the movement we see in A1c. They all work by lowering blood sugar day to day, which is what the test averages:
Cut refined sugar and refined starch first. It is the change most people can start today, and A1c takes eight to twelve weeks to reflect it.
Lose weight if there is weight to lose. The dose-response here is steep, as the numbers below show.
Walk after meals. Post-meal movement blunts the glucose spike that drives glycation.
Raise fiber and protein at the expense of liquid carbohydrate. Fruit juice and soda are the usual culprits, and fructose in particular does damage out of proportion to its calories.
Measure. Retest A1c every three months, because that is the window the test actually covers.
Lifestyle changes can profoundly affect HbA1c levels. A diet rich in whole foods, low in refined sugars, and high in fiber significantly helps control blood glucose. For instance, individuals adopting a Mediterranean diet, which is abundant in fruits, vegetables, whole grains, and healthy fats, often see HbA1c reductions of about 0.3 percentage points against control diets, pooled across nine randomized trials in people with type 2 diabetes (mean difference −0.30%, 95% confidence interval −0.46 to −0.14; Huo et al., European Journal of Clinical Nutrition, 2015).
Moreover, weight loss plays a crucial role in improving glycemic control. Research indicates that losing just 5-10% of body weight can lead to a reduction in HbA1c levels, translating to better health outcomes. This is especially relevant for individuals with type 2 diabetes; studies show that participants who achieved modest weight loss experienced improvements in blood sugar management that can last for years.
The DiRECT trial put hard numbers on this. It enrolled people aged 20 to 65 who had been diagnosed with type 2 diabetes within the previous six years, with a body mass index of 27 to 45, and who were not on insulin. Of the participants who lost 15 kg or more, 86% achieved remission of type 2 diabetes, defined as an HbA1c below 6.5% after at least two months off all antidiabetic medication, although only 36 of the 149 people in the intervention group, 24%, lost that much. At 10 to 15 kg remission was 57%, at 5 to 10 kg it was 34%, and in the control group only 4%. Weight loss is not one factor among many here. It is the dominant one. For patients who cannot get there on diet alone, GLP-1 medications are one of the options we discuss.
Open-ended timelines exist for observing life expectancy and healthspan improvements post-HbA1c reduction. However, sustained reductions in HbA1c typically coincide with lower risks of chronic diseases. Regular monitoring and management of blood sugar create a pathway to better health. Because A1c reflects two to three months of glucose, there is no point retesting sooner than that. Every three months is the right cadence, and our lab testing panel runs A1c alongside fasting insulin, which together tell you far more than either alone.
Additionally, managing your HbA1c has psychological benefits. People often feel a sense of control and empowerment as they actively work to lower their HbA1c. This can lead to healthier lifestyle choices and contribute to a better quality of life. Social connections and community engagement often increase alongside improved health, contributing significantly to longevity.
As technology advances, monitoring blood sugar has become easier. Continuous glucose monitors (CGMs) allow users to get real-time feedback and quickly adjust their diets and activities. Using these tools can lower HbA1c by roughly 0.3% on average across randomized trials in type 2 diabetes (Journal of Clinical Endocrinology & Metabolism, 2024), and the real benefit is often behavioral: seeing what a particular meal does to your glucose changes what you eat next time, providing a simple yet effective way of taking charge of one's health.
Taking Charge of Your Health
The correlation between HbA1c levels, the Maillard reaction, and overall health is significant. Reducing HbA1c not only lowers the risk for chronic diseases but also enhances life quality and longevity. By making informed choices about diet and exercise, individuals can improve their health outcomes.
Ultimately, effective management of HbA1c through lifestyle changes and modern technology empowers people to live healthier lives. As more research highlights the importance of understanding and controlling HbA1c, healthcare professionals must prioritize this knowledge among their patients to promote better health outcomes.
Investing in health education and support systems can foster a community focus on maintaining healthy HbA1c levels. By striving for these values, we pave the way to a longer, healthier life for everyone.
If your A1c has been creeping upward and you would like it interpreted alongside the rest of your metabolic picture, our diabetes and metabolic care page explains how we approach it, and you can request an appointment here.
Anti-Aging and HbA1c
Hemoglobin A1c (HbA1c) is a crucial biomarker that reflects long-term glycemic control and serves as a predictor of various age-related diseases. Chronic hyperglycemia, even in the absence of overt diabetes, accelerates the aging process through multiple mechanisms, including increased oxidative stress, glycation of proteins, and chronic low-grade inflammation. Elevated HbA1c levels correlate with an increased risk of cardiovascular disease, neurodegenerative disorders, and frailty, all of which are hallmarks of accelerated aging. By maintaining an optimal HbA1c level, individuals may reduce the risk of age-related comorbidities, improve metabolic resilience, and enhance longevity. This is the same mechanism we describe in our article on insulin resistance as a precursor to cardiovascular disease, dementia and accelerated aging.
One of the primary mechanisms by which HbA1c influences aging is through advanced glycation end-products (AGEs). These glycated proteins accumulate over time and contribute to tissue stiffness, endothelial dysfunction, and neurodegeneration. AGEs also activate receptor-mediated pathways that promote inflammation and oxidative damage, both of which are central to the aging process. Research has demonstrated that individuals with lower HbA1c levels exhibit reduced AGE accumulation, leading to improved vascular function and cognitive performance in later life. Thus, tight glycemic control can mitigate the formation of AGEs and their deleterious effects on aging.
Beyond metabolic and vascular health, HbA1c levels are also linked to telomere attrition, a well-established marker of cellular aging. Hyperglycemia-induced oxidative stress accelerates telomere shortening, which in turn leads to cellular senescence and impaired regenerative capacity. Studies suggest that individuals with well-controlled HbA1c have longer telomeres compared to those with poorly controlled blood glucose levels (Uziel et al., 2007, in patients with type 1 and type 2 diabetes). Since telomere integrity is closely tied to overall longevity and healthspan, maintaining a low HbA1c may serve as a strategy to delay cellular aging and enhance tissue repair mechanisms.
Furthermore, HbA1c plays a critical role in neuroprotection against age-related cognitive decline. Elevated glucose levels promote neuroinflammation and impair insulin signaling in the brain, contributing to cognitive impairment and an increased risk of Alzheimer's disease. A growing body of evidence links higher HbA1c levels with poorer cognitive function and greater amyloid deposition, a hallmark of neurodegeneration (Biessels & Despa, 2018). By optimizing glycemic control, individuals may be able to preserve cognitive function and reduce their risk of developing dementia in old age. Cognitive function itself is measurable, and we track it directly with Cognivue testing.
In conclusion, HbA1c is not merely a marker for diabetes but a key determinant of the aging process. By maintaining HbA1c within an optimal range, individuals can minimize oxidative stress, prevent the formation of AGEs, preserve telomere length, and protect against neurodegeneration. These factors collectively contribute to improved longevity and a higher quality of life in aging populations. As research continues to uncover the intricate connections between glucose metabolism and aging, HbA1c may emerge as an essential target for anti-aging interventions.
Nutraceuticals that can lower HbA1c, Lower Blood Sugar and even more:
Frequently asked questions
What is the optimal A1c for longevity?
UKPDS 35 followed people with newly diagnosed type 2 diabetes. In that group, risk was lowest in those whose HbA1c sat below 6.0%, and across the range the study observed, no threshold of risk was found for any endpoint. That finding is about people with type 2 diabetes and does not transfer automatically to everyone else. In 11,092 adults without diabetes in the ARIC study, HbA1c and death from any cause followed a J-shaped curve, measured against a reference band of 5.0% to under 5.5% (Selvin et al., New England Journal of Medicine, 2010), meaning risk was higher both above and below that band. An A1c under 5% is the target I set out above for a metabolically healthy patient who is not on glucose-lowering medication. It is a clinical judgement, made alongside the rest of a patient's metabolic picture, rather than a number the evidence converges on, and it is a target to agree with your own physician rather than to chase alone. For someone on insulin or a sulfonylurea, the target is set individually because hypoglycemia carries its own risk.
How quickly can you lower your A1c?
A1c reflects the previous two to three months, so it lags behind the change you make. The first meaningful movement shows up at around eight to twelve weeks, which is why we retest at three months rather than sooner. A test taken a few weeks after a change tells you very little.
Is an A1c of 6.7% dangerous?
Not dangerous in the sense of needing urgent care, but it is high. An A1c of 6.7% corresponds to an estimated average glucose of about 146 mg/dL, and it sits above the 6.5% diagnostic threshold for diabetes, which works out at about 140 mg/dL (Nathan et al., Diabetes Care, 2008). It warrants a full metabolic workup rather than watchful waiting.
Does A1c rise naturally with age?
A1c does drift upward slightly with age even in people without diabetes, but the drift is small. In the Framingham Offspring Study and NHANES it worked out at roughly 0.010 to 0.014 percentage points a year in people without diabetes (Pani et al., Diabetes Care, 2008). That drift persisted in the subgroup with normal glucose tolerance and after adjustment for sex, BMI, fasting glucose and two-hour post-load glucose, so it is not simply early insulin resistance showing up in the number. Diagnostic thresholds are not age-specific, so a mildly raised A1c in an older patient still warrants a proper look rather than an assumption that it is only age.
Can lowering A1c reverse damage already done?
Partly. Microvascular risk falls with sustained control, but over years rather than weeks, and improvement is not always immediate: in the DCCT, which studied type 1 diabetes, some patients had a transient early worsening of retinopathy in the first year before the long-term benefit appeared (Archives of Ophthalmology, 1998). Advanced glycation end products already deposited in long-lived tissue proteins are thought to turn over slowly, which is the argument for acting during the prediabetic window rather than after a diagnosis.
General Health References
American Diabetes Association. (2020). Standards of Medical Care in Diabetes—2020. Diabetes Care, 43(Supplement 1), S1-S212.
Stratton, I. M., Adler, A. I., Neil, H. A. W., Matthews, D. R., Manley, S. E., Cull, C. A., Hadden, D., Turner, R. C., & Holman, R. R. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321(7258), 405-412. https://www.bmj.com/content/321/7258/405
Emerging Risk Factors Collaboration. (2023). Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation. The Lancet Diabetes & Endocrinology, 11(10), 731-742. https://pubmed.ncbi.nlm.nih.gov/37708900/
Lean, M. E. J., Leslie, W. S., Barnes, A. C., et al. (2018). Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. The Lancet, 391(10120), 541-551. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33102-1/abstract
Action to Control Cardiovascular Risk in Diabetes Study Group. (2008). Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine, 358(24), 2545-2559. https://www.nejm.org/doi/full/10.1056/NEJMoa0802743
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010). Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. New England Journal of Medicine, 362(9), 800-811. https://www.nejm.org/doi/full/10.1056/NEJMoa0908359
Prasad, C., Davis, K. E., Imrhan, V., Juma, S., & Vijayagopal, P. (2019). Advanced glycation end products and risks for chronic diseases: intervening through lifestyle modification. American Journal of Lifestyle Medicine, 13(4), 384-404. https://pmc.ncbi.nlm.nih.gov/articles/PMC6600625/
Uhl, S., Choure, A., Rouse, B., Loblack, A., & Reaven, P. (2024). Effectiveness of continuous glucose monitoring on metrics of glycemic control in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. The Journal of Clinical Endocrinology & Metabolism, 109(4), 1119-1131. https://academic.oup.com/jcem/article/109/4/1119/7438972
Huo, R., Du, T., Xu, Y., Xu, W., Chen, X., Sun, K., & Yu, X. (2015). Effects of Mediterranean-style diet on glycemic control, weight loss and cardiovascular risk factors among type 2 diabetes individuals: a meta-analysis. European Journal of Clinical Nutrition, 69(11), 1200-1208. https://doi.org/10.1038/ejcn.2014.243
Pani, L. N., Korenda, L., Meigs, J. B., Driver, C., Chamany, S., Fox, C. S., Sullivan, L., D'Agostino, R. B., & Nathan, D. M. (2008). Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care, 31(10), 1991-1996. https://doi.org/10.2337/dc08-0577
Diabetes Control and Complications Trial Research Group. (1998). Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Archives of Ophthalmology, 116(7), 874-886. https://pubmed.ncbi.nlm.nih.gov/9682700/
Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., & Nathan, D. M. (Diabetes Prevention Program Research Group). (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346(6), 393-403. https://pubmed.ncbi.nlm.nih.gov/11832527/
Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., & Heine, R. J. (2008). Translating the A1C assay into estimated average glucose values. Diabetes Care, 31(8), 1473-1478. https://doi.org/10.2337/dc08-0545
Centers for Disease Control and Prevention. A1C Test for Diabetes and Prediabetes. https://www.cdc.gov/diabetes/diabetes-testing/prediabetes-a1c-test.html
American Diabetes Association. Understanding A1C: what it measures and why it matters. https://diabetes.org/about-diabetes/a1c
Anti-Aging References (with quick links to the articles)
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The hallmarks of aging. Cell, 153(6), 1194-1217. https://doi.org/10.1016/j.cell.2013.05.039
Singh, R., Barden, A., Mori, T., & Beilin, L. (2001). Advanced glycation end-products: a review. Diabetologia, 44(2), 129-146. https://doi.org/10.1007/s001250051591
Salpea, K. D., Talmud, P. J., Cooper, J. A., Maubaret, C. G., Stephens, J. W., Abelak, K., & Humphries, S. E. (2010). Association of telomere length with type 2 diabetes, oxidative stress and UCP2 gene variation. Atherosclerosis, 209(1), 42-50. https://doi.org/10.1016/j.atherosclerosis.2009.09.070
Uziel, O., Singer, J. A., Danicek, V., Sahar, G., Berkov, E., Luchansky, M., Fraser, A., Ram, R., & Lahav, M. (2007). Telomere dynamics in arteries and mononuclear cells of diabetic patients: effect of diabetes and of glycemic control. Experimental Gerontology, 42(10), 971-978. https://doi.org/10.1016/j.exger.2007.07.005
Biessels, G. J., & Despa, F. (2018). Cognitive decline and dementia in diabetes mellitus: Mechanisms and clinical implications. Nature Reviews Endocrinology, 14(10), 591-604. https://doi.org/10.1038/s41574-018-0048-7
Fontana, L., Kennedy, B. K., Longo, V. D., Seals, D., & Melov, S. (2014). Medical research: Treat ageing. Nature, 511(7510), 405-407. https://doi.org/10.1038/511405a
David S. Klein, MD, FACA, FACPM
1917 Boothe Circle, Suite 171
Longwood, Florida 32750
Tel: 407-679-3337
Fax: 407-678-7246
.webp)